Brain-penetrating acetylcholinesterase reactivators for several organophosphates

几种有机磷酸酯的脑穿透性乙酰胆碱酯酶再激活剂

• 批准号: 9331890
• 负责人: Janice Elaine Chambers
• 金额: $ 14.49万
• 依托单位: MISSISSIPPI STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9331890
• 关键词: Accidents; Accounting; Acetylcholinesterase; Acetylcholinesterase Inhibitors; Atropine; Attenuated; Behavior; Behavioral; Binding Proteins; Blood; Blood - brain barrier anatomy; Brain; Brain Injuries; Cerebrospinal Fluid; Cessation of life; Chemicals; Chemistry; Cholinesterase Inhibitors; Cognitive deficits; Convulsants; Development; Diazepam; Docking; Dose; Drug Kinetics; Exposure to; F2-Isoprostanes; General Population; Glial Fibrillary Acidic Protein; Goals; Health; Hepatic; In Vitro; Insecticides; Japanese Population; Laboratories; Lead; Libraries; Life; Long-Term Effects; Measures; Metabolism; Microdialysis; Mississippi; Modeling; Muscarinic Antagonists; Nerve Degeneration; Nervous System Trauma; Neurologic; Organophosphates; Outcome; Oxidative Stress; Oximes; Paraoxon; Parathion; Penetration; Peripheral; Peripheral Nervous System; Plasma Proteins; Poison; Poisoning; Publishing; Rattus; Research Project Grants; Risk; Sarin; Seizures; Structure; Subway; Survivors; Synthesis Chemistry; Testing; Therapeutic Agents; Translational Research; Universities; attenuation; chemical synthesis; computational chemistry; design; dosage; efficacy testing; excitotoxicity; improved; in vivo; inorganic phosphate; lipophilicity; molecular dynamics; nerve agent; neuron apoptosis; neuropathology; neuroprotection; novel; novel therapeutics; organophosphate poisoning; prevent; research study; screening; toxic organophosphate insecticide exposure

DESCRIPTION (provided by applicant): Organophosphate (OP) anticholinesterases, e.g., nerve agents or insecticides, are potent acetylcholinesterase (AChE) inhibitors. High dose poisoning causes excitotoxicity that leads to seizures and subsequently brain damage. The current therapy in the US includes an oxime reactivator, 2-PAM, which has little, if any, ability t cross the blood-brain barrier (BBB) and consequently cannot stop seizures and prevent brain damage. Our laboratories have developed a library of phenoxyalkyl pyridinium oximes designed to have greater lipophilicity than 2-PAM. Through a paradigm using high sub-lethal dosages of highly relevant surrogates for sarin or VX in rats and administering the novel oximes at 1 hr after OP compound treatment when seizure behavior was on- going, we have demonstrated the ability of a number of these oximes to penetrate the BBB, reactivate AChE, and to attenuate seizure behavior. The objective of this application is to further characterize a limited number of these novel oximes (initially 6, then down-selected to 3) to ultimately select a single lead oxime for an IND application. Additionally we will expand the OP chemistries tested to include an insecticidal chemistry, paraoxon (the active metabolite of parathion; tested first to avoid any confounders that could occur because of the need for bioactivation) and parathion. Endpoints of characterization include brain and peripheral AChE reactivation, seizure attenuation, neurodegeneration (glial fibrillary acidic protein accumulation), oxidative stress (F2-isoprostanes), neuropathology (apoptosis, neuron survival), and behavior. Concurrently molecular dynamics computations will determine if one or two additional oxime structures are predicted to have greater efficacy than our current selections; if so, it/they will be synthesized and substituted for our current selections. The specific aims of the proposed project are: 1. In vivo efficacy characterization aim: To provide expanded measures of neuroprotection on our currently identified BBB-penetrating oximes using the sarin and VX surrogates and also a common insecticidal OP chemistry (i.e., diethyl phosphate) using parathion and its active metabolite paraoxon. Efficacy endpoints for the 4 OP's include: 1a, efficacy screening endpoints with 6 oximes: reactivating rat brain AChE, and the attenuation of seizure behavior and neurodegeneration; and 1b, detailed efficacy characterization endpoints with 3 down-selected oximes: oxidative stress in the brain, neuropathology and behavioral deficits. 2. Pharmacokinetic aim: To determine for the 3 down-selected oximes hepatic in vitro metabolism, plasma protein binding and levels of oxime in the blood and cerebrospinal fluid (obtained through microdialysis). 3. Computational chemistry aim: To model the docking of oxime with AChE and BBB penetration to suggest improved oxime structures. 4. Chemical synthesis aim: To produce sufficient quantities of the test OP's and the test oximes for the experiments proposed, as well as the synthesis of a few new oximes if suggested by the computational chemistry aim. The ultimate outcome will be the identification of the most efficacious novel oxime for further development as a potential substitute for current therapy.

描述（由申请人提供）：有机磷（OP）抗胆碱酯酶，如神经毒剂或杀虫剂，是有效的乙酰胆碱酯酶（AChE）抑制剂。高剂量中毒会引起兴奋性中毒，导致癫痫发作和随后的脑损伤。美国目前的治疗方法包括一种肟再激活剂2-PAM，它几乎没有穿越血脑屏障（BBB）的能力，因此不能阻止癫痫发作和防止脑损伤。我们的实验室已经开发了一个文库的苯氧烷基吡啶肟设计具有更大的亲脂性比2-PAM。通过在大鼠中使用高亚致死剂量的高度相关的沙林或VX替代品，并在1小时后给予新型肟